[Bronchopulmonary dysplasia].

OBJECTIVE To present a wide-ranging review of the literature on broncopulmonary dysplasia, covering new definitions, pathophysiology, prevention, treatment, prognosis and progression. SOURCES OF DATA The most relevant articles published on the subject since it was first described in 1967 were selected from MEDLINE search results. SUMMARY OF THE FINDINGS Bronchopulmonary dysplasia is considered one of the primary causes of chronic lung disease among infants. It is associated with frequent and prolonged hospital admissions, in particular for pulmonary diseases, with high rates of mortality and alterations to neuropsychomotor development and pondero-statural growth. Pathogenesis is complex, being primarily influenced by prematurity, infection, supplementary oxygen and mechanical ventilation. Prevention involves appropriate prenatal care, the prevention of premature delivery, prenatal corticosteroids, surfactant replacement therapy and "protective" ventilatory strategies. Treatment of bronchopulmonary dysplasia patients demands a multidisciplinary team. When indicated, oxygen supplementation is extremely important. Despite increased risk of morbidity and mortality during the first years of life, long term progress is favorable in the majority of cases. CONCLUSIONS Bronchopulmonary dysplasia has been and continues to be studied in great depth with the objective of identifying its causes and possible prevention and treatment strategies. Controversies remain with respect of these issues and also about the prognosis of these patients, in particular when the subject is long-term progress of "new" bronchopulmonary dysplasia patients.

[1]  L. Brion,et al.  Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. , 2011, The Cochrane database of systematic reviews.

[2]  L. Brion,et al.  Aerosolized diuretics for preterm infants with (or developing) chronic lung disease. , 2006, The Cochrane database of systematic reviews.

[3]  A. Jobe.  Postnatal corticosteroids for preterm infants--do what we say, not what we do. , 2004, The New England journal of medicine.

[4]  J. Ribeiro,et al.  Maternal and neonatal factors affecting the incidence of bronchopulmonary dysplasia in very low birth weight newborns , 2003 .

[5]  O. Saugstad,et al.  Treatment strategies for bronchopulmonary dysplasia with postnatal corticosteroids in Europe: the EURAIL survey * , 2003, Acta paediatrica.

[6]  A. Greenough,et al.  Post-natal corticosteroid use , 2003, European Journal of Pediatrics.

[7]  R. Primhak.  Discharge and aftercare in chronic lung disease of the newborn. , 2003, Seminars in neonatology : SN.

[8]  B. Böhm,et al.  Cognitive development at 5.5 years of children with chronic lung disease of prematurity , 2003, Archives of disease in childhood. Fetal and neonatal edition.

[9]  D. Grier,et al.  Corticosteroids in the prevention and management of bronchopulmonary dysplasia. , 2003, Seminars in neonatology : SN.

[10]  B. Darlow,et al.  Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants. , 2002, The Cochrane database of systematic reviews.

[11]  Arthur S Slutsky,et al.  Lung injury in neonates: causes, strategies for prevention, and long-term consequences. , 2001, The Journal of pediatrics.

[12]  R. Auten,et al.  Volutrauma. What is it, and how do we avoid it? , 2001, Clinics in perinatology.

[13]  C. Cole.  Postnatal glucocorticoid therapy for prevention of bronchopulmonary dysplasia: routes of administration compared. , 2001, Seminars in neonatology : SN.

[14]  H. Van Bever,et al.  The role of inflammation in the development of chronic lung disease in neonates , 2001, European Journal of Pediatrics.

[15]  A. Jobe,et al.  Prevention of bronchopulmonary dysplasia , 2001, Current opinion in pediatrics.

[16]  S. Atkinson.  Special nutritional needs of infants for prevention of and recovery from bronchopulmonary dysplasia. , 2001, The Journal of nutrition.

[17]  K. Barrington.  The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs , 2001, BMC pediatrics.

[18]  E. von Mutius,et al.  Paediatric origins of adult lung disease , 2001, Thorax.

[19]  J. Davis,et al.  Superoxide dismutase for preventing chronic lung disease in mechanically ventilated preterm infants. , 2001, The Cochrane database of systematic reviews.

[20]  Anne Synnes,et al.  Variations in Practice and Outcomes in the Canadian NICU Network: 1996–1997 , 2000, Pediatrics.

[21]  A. Lyon.  Chronic lung disease of prematurity. The role of intra-uterine infection , 2000, European Journal of Pediatrics.

[22]  P. Papoff,et al.  Infection, neutrophils, and hematopoietic growth factors in the pathogenesis of neonatal chronic lung disease. , 2000, Clinics in perinatology.

[23]  A. Greenough.  Measuring respiratory outcome. , 2000, Seminars in neonatology : SN.

[24]  P. Davis,et al.  Postnatal corticosteroids in preterm infants: Systematic review of effects on mortality and motor function , 2000, Journal of paediatrics and child health.

[25]  C. Cole.  Postnatal glucocorticosteroid therapy for treatment and prevention of neonatal chronic lung disease , 2000, Expert opinion on investigational drugs.

[26]  C. Cole.  Inhaled Glucocorticoid Therapy in Infants at Risk for Neonatal Chronic Lung Disease , 2000, The Journal of asthma : official journal of the Association for the Care of Asthma.

[27]  J. Kennedy.  Lung function outcome in children of premature birth , 1999, Journal of paediatrics and child health.

[28]  I. Frantz,et al.  Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. , 1999, The New England journal of medicine.

[29]  H. Halliday.  Clinical Trials of Postnatal Corticosteroids: Inhaled and Systemic , 1999, Neonatology.

[30]  A. Jobe,et al.  Mechanisms initiating lung injury in the preterm. , 1998, Early human development.

[31]  K. Barrington,et al.  Treatment of bronchopulmonary dysplasia. A review. , 1998, Clinics in perinatology.

[32]  J. Kimpen,et al.  Ureaplasma urealyticum colonization, prematurity and bronchopulmonary dysplasia. , 1997, The European respiratory journal.

[33]  K. Mcculloch,et al.  Vitamin a Deficiency and Severe Bronchopulmonary Dysplasia in Very Low Birth Weight Infants , 1996, American journal of perinatology.

[34]  E. Bancalari,et al.  Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. , 1995, The Journal of pediatrics.

[35]  D. Phelps,et al.  Predicting risk for bronchopulmonary dysplasia: selection criteria for clinical trials. , 1990, Pediatrics.

[36]  A. Ohlsson,et al.  Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. , 1988, Pediatrics.

[37]  E. Bancalari,et al.  Bronchopulmonary dysplasia: clinical presentation. , 1979, The Journal of pediatrics.

[38]  V. Chernick,et al.  Pulmonary fibroplasia following prolonged artificial ventilation of newborn infants. , 1969, Canadian Medical Association journal.

[39]  W. H. Hendren,et al.  Pulmonary disease following respiratory therapy of hyaline-membrane disease :W. H. Northway, Jr., R. C. Rosan and D. Y. Porter. New Eng. J. Med. 276:357–368, February 1967 , 1967 .

[40]  W. Northway,et al.  Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. , 1967, The New England journal of medicine.

[41]  H. Halliday,et al.  Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. , 2007, The Cochrane database of systematic reviews.

[42]  L. Doyle,et al.  Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. , 2003, The Cochrane database of systematic reviews.

[43]  P. Shah,et al.  Current Perspectives on the Prevention and Management of Chronic Lung Disease in Preterm Infants , 2003, Paediatric drugs.

[44]  L. Ho,et al.  Bronchopulmonary Dysplasia and Chronic Lung Disease of Infancy: Strategies for Prevention and Management Continuing Professional Development , 2022 .

[45]  E. Bancalari,et al.  Bronchopulmonary dysplasia. , 1986, Pediatric clinics of North America.

[46]  H. Halliday,et al.  Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. , 2000, The Cochrane database of systematic reviews.

[47]  Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants. , 1998, Pediatrics.